SCHEMBL4735152

SCHEMBL4735152

CCc1ccnc(C(=O)C=CN(C)C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.46
SMYD3 Q9H7B4 1/20 0.46
MAPT P10636 9/20 0.46
ALDH1A1 P00352 7/20 0.46
RAB9A P51151 6/20 0.46
NPC1 O15118 4/20 0.46
KMT2A Q03164 1/20 0.46
RECQL P46063 2/20 0.45
GAA P10253 3/20 0.44
HPGD P15428 2/20 0.42
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
NOS3 P29474 1/20 0.40
NOS1 P29475 1/20 0.40
NOS2 P35228 1/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
ALOX12 P18054 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
CTSA P10619 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4734764 0.89 MAPT (0.57) HTTSMYD3MAPTALDH1A1RAB9A
SCHEMBL14651335 0.85 MAPT (0.44) HTTMAPTALDH1A1RAB9ANPC1
SCHEMBL12501401 0.85 MAPT (0.44) HTTMAPTALDH1A1RAB9ANPC1
SCHEMBL7239456 0.80 HTT (0.50) HTTMAPTALDH1A1RAB9ANPC1
SCHEMBL4736636 0.80 HTT (0.50) HTTMAPTALDH1A1RAB9ANPC1
SCHEMBL24369170 0.79 ALDH1A1 (0.53) HTTMAPTALDH1A1RAB9ANPC1
SCHEMBL14651339 0.79 MAPT (0.59) HTTMAPTALDH1A1RAB9ANPC1
SCHEMBL29488881 0.79 MAPT (0.59) HTTMAPTALDH1A1RAB9ANPC1
SCHEMBL14651291 0.79 MAPT (0.59) HTTMAPTALDH1A1RAB9ANPC1
SCHEMBL12501384 0.79 MAPT (0.59) HTTMAPTALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2668177-B1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INT (DE) 2014-10-22 EP disclosed
US-8772305-B2 Substituted pyridinyl-pyrimidines and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-08 US disclosed
EP-2668177-A1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS Boehringer Ingelheim International GmbH (DE) 2013-12-04 EP disclosed
US-8466154-B2 Methods and compositions related to wrapping of dehydrons THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-06-18 US disclosed
US-20130131076-A1 METHODS AND COMPOSITIONS RELATED TO WRAPPING OF DEHYDRONS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-05-23 US disclosed
US-20130023502-A1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-24 US disclosed
WO-2012101013-A1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-02 WO disclosed
WO-2008070350-A9 METHODS AND COMPOSITIONS RELATED TO WRAPPING OF DEHYDRONS UNIV TEXAS (US) 2008-10-23 WO disclosed
WO-2008070350-A2 METHODS AND COMPOSITIONS RELATED TO WRAPPING OF DEHYDRONS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023502-A1 SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS ADORA1, P2RY1, P2RY11 HTT 4752/4885SMYD3 3817/4885MAPT 4540/4885
US-20130131076-A1 METHODS AND COMPOSITIONS RELATED TO WRAPPING OF DEHYDRONS DKK1, HPN, OSBP2 HTT 4052/4885SMYD3 2176/4885MAPT 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.